Courtagen Life Sciences Appoints Dr. Joe Keegan to the Company's Board of Directors
Keegan Adds Deep Operating Life Science Expertise to Courtagen's Expanding Operations
May 12, 2015, Woburn, MA --Courtagen Life Sciences, Inc., a commercial-stage, innovative molecular information company that sells proprietary genomic diagnostic and drug metabolism assays for pediatric neurology disorders, announced today the appointment of Dr. Joe Keegan to the company’s Board of Directors.
“Dr. Keegan’s previous success in building private and public companies in the life sciences industry will add a valuable perspective to our Board of Directors,” states Brian McKernan, Chief Executive Officer of Courtagen. “We look forward to benefiting from Joe’s insights, and having him on the Courtagen Team.”
Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M , and exited the company in 2012 through its sale to Pall Corporation for a return to investors of $160M. During his 9 year tenure as CEO at Molecular Devices Corporation, Dr. Keegan grew the company's revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Boards of Directors of Advanced Cell Diagnostics, Courtagen Life Sciences, Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation (RBM:Toronto), Seahorse Bioscience Inc., Stereotaxis, Inc. (Nasdaq: STXS), Unchained Labs, Inc., Wasatch Microfluidics, Inc., ALDA as Past Chairman and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
About Courtagen Life Sciences, Inc.
Courtagen is a privately held life sciences and molecular information company that converts genomic data into actionable clinical information for the diagnosis of critical pediatric neurological and metabolic disorders. Specifically, Courtagen focuses on mitochondrial disorders, epilepsy, and intellectual disability, including autism spectrum disorders. Courtagen’s state-of-the-art Next-Generation Sequencing clinical laboratory integrates genotype, phenotype, and disease mechanism data using cloud-based computing and custom analytical methods to provide the most comprehensive results for clinicians, patients, and their families to better understand and treat their disease. More information can be found at www.courtagen.com.
Courtagen Life Sciences, Inc.
Mike Catalano, 877-395-7608